UroGen Pharma (URGN) Common Equity (2016 - 2025)
Historic Common Equity for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$115.4 million.
- UroGen Pharma's Common Equity fell 55231.43% to -$115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.4 million, marking a year-over-year decrease of 55231.43%. This contributed to the annual value of -$8.8 million for FY2024, which is 8650.1% up from last year.
- Latest data reveals that UroGen Pharma reported Common Equity of -$115.4 million as of Q3 2025, which was down 55231.43% from -$93.4 million recorded in Q2 2025.
- Over the past 5 years, UroGen Pharma's Common Equity peaked at $76.5 million during Q1 2021, and registered a low of -$138.4 million during Q2 2023.
- In the last 5 years, UroGen Pharma's Common Equity had a median value of -$40.9 million in 2022 and averaged -$34.1 million.
- Per our database at Business Quant, UroGen Pharma's Common Equity crashed by 116217.76% in 2022 and then surged by 16076.01% in 2024.
- Quarter analysis of 5 years shows UroGen Pharma's Common Equity stood at $8.4 million in 2021, then tumbled by 1162.18% to -$89.4 million in 2022, then increased by 27.02% to -$65.2 million in 2023, then skyrocketed by 86.5% to -$8.8 million in 2024, then crashed by 1211.01% to -$115.4 million in 2025.
- Its Common Equity stands at -$115.4 million for Q3 2025, versus -$93.4 million for Q2 2025 and -$46.5 million for Q1 2025.